Count G1 Therapeutics and Revolution Medicines among the biotechnology companies benefitting from a 2014 boom in venture capital funding that has spilled over into 2015.
Cancer-focused G1 in Research Triangle Park, North Carolina raised a $33m Series B VC funding round to advance its Phase...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
